These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68. The prognostic value of cell surface antigens in low grade, non-invasive, transitional cell carcinoma of the bladder. Young AK; Hammond E; Middleton AW J Urol; 1979 Oct; 122(4):462-4. PubMed ID: 480485 [TBL] [Abstract][Full Text] [Related]
72. Evaluation of cellular immunity following bacillus Calmette-Guérin therapy in patients with superficial bladder cancer. Sarica K; Baltaci S; Bedük Y; Süzer O; Kiliç S; Müftüğlu YZ; Göğüş O Urol Int; 1995; 54(3):137-41. PubMed ID: 7604454 [TBL] [Abstract][Full Text] [Related]
73. Balancing effectiveness and toxicity of levamisole in the treatment of rheumatoid arthritis. Runge LA; Rynes RI Clin Exp Rheumatol; 1983; 1(2):125-31. PubMed ID: 6398156 [TBL] [Abstract][Full Text] [Related]
75. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. Lamm DL; Blumenstein BA; Crissman JD; Montie JE; Gottesman JE; Lowe BA; Sarosdy MF; Bohl RD; Grossman HB; Beck TM; Leimert JT; Crawford ED J Urol; 2000 Apr; 163(4):1124-9. PubMed ID: 10737480 [TBL] [Abstract][Full Text] [Related]
76. Levamisole in advanced human breast cancer. Rojas AF; Feierstein JN; Mickiewicz E; Glait H; Olivari AJ Lancet; 1976 Jan; 1(7953):211-5. PubMed ID: 55529 [TBL] [Abstract][Full Text] [Related]
77. Sequential immunocytological evaluation of murine transitional cell carcinoma during intralesional bacillus Calmette-Guerin and interleukin-2 immunotherapy. Sosnowski JT; De Haven JI; Abraham FM; Riggs DR; Lamm DL J Urol; 1992 May; 147(5):1439-43. PubMed ID: 1569700 [TBL] [Abstract][Full Text] [Related]
78. Efficacy of bacillus Calmette-Guérin in the treatment of superficial bladder cancer: the impact of previous intravesical treatment. Okamura T; Akita H; Imura M; Kaneko T; Mizuno K; Tozawa K; Kohri K Int J Urol; 2008 Oct; 15(11):976-80. PubMed ID: 18721199 [TBL] [Abstract][Full Text] [Related]
80. Phase III randomised chemoprevention study with selenium on the recurrence of non-invasive urothelial carcinoma. The SELEnium and BLAdder cancer Trial. Goossens ME; Zeegers MP; van Poppel H; Joniau S; Ackaert K; Ameye F; Billiet I; Braeckman J; Breugelmans A; Darras J; Dilen K; Goeman L; Tombal B; Van Bruwaene S; Van Cleyenbreugel B; Van der Aa F; Vekemans K; Buntinx F Eur J Cancer; 2016 Dec; 69():9-18. PubMed ID: 27814472 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]